Ruti Aga's Six-Year Ban: A Forged Prescription Turned a Two-Year Absence into Career Death

The sample Ruti Aga gave after winning a half marathon in China in March came back positive. Had the case stopped there, it would have been a two-year ban — a glucocorticoid (methylprednisolone) used in-competition, a case in which the athlete had a legitimate defence: treatment for a knee injury. Instead, Aga submitted a prescription from a clinic that did not exist, signed by a 'doctor' who was a family member with no medical registration. According to the Athletics Integrity Unit (AIU) statement issued on Thursday, that forgery turned a two-year suspension into six. Effective from 10 September, the ban will return the 32-year-old Aga at 38 — which, in Ethiopia's marathon depth, is effectively a lifetime ban for a sanctioned athlete. The real story here is not the substance but the document. On WADA's Prohibited List, methylprednisolone is classified not as an anabolic steroid (S1) but as a glucocorticoid (S9), and it is prohibited only in-competition. An injection into the knee is entirely legal out-of-competition and becomes a violation only if residue is present on race day. That technicality was Aga's escape route: had the date, route and medical necessity of the injection been documented, the case could have fallen into 'no fault' or 'no significant fault' territory. According to the AIU statement, the clinic on whose name the prescription was issued explicitly disowned it — the doctor had no registration, and the explanation offered was an 'old pad from a former workplace.' Three independent verification failures. The sanction arithmetic is straightforward: two years for the presence violation, four years for tampering — six in total. This structure tells us the panel found the substance case proven but held the document manipulation fully culpable. What draws attention is that the forged prescription is itself circumstantial evidence of concealment intent, yet it did not escalate the presence sanction — the panel kept the two in separate boxes. In my experience, from the 2026 Dutee Chand CAS case to the 2026 Asian Cup tournament-rules crisis, the disciplinary outcomes I have seen follow this pattern: an athlete's fate is often decided not by the substance but by what happens afterwards. The most important part of this case is what is not in the statement. The AIU named only the family member as the 'doctor'; it did not say whether the agent or management was investigated. A 2:18–2:20-level marathon runner with a 2026 Tokyo Marathon title and three World Marathon Majors second places has access to internationally recognised medical support — yet the treatment document was produced by an unregistered relative. This signals a system more than a personal lapse: in East African road racing, the pressure to hide chronic knee injury (to protect appearance-fee income) and the availability of cheap glucocorticoid injections combine to create a medical gap with no TUE (Therapeutic Use Exemption) culture. The result: the injury is real, the treatment is real, but the paperwork is fake — and the sanction lands on the paperwork. A sharp question arises that I want to put without wrapping: is a six-year ban for a substance with no proven endurance benefit evidence of AIU rigour or of disproportionate enforcement against African road runners? Both readings may be correct. But whichever it is, the lesson is clear: the fake document was the one thing that turned a debatable case into a firm sanction. What survives is the 2026 Tokyo title and three Major podiums, because the ban is anchored to the March race and the statement does not mention annulment of earlier results — although AIU's standard practice is to annul the result and prize money of the competition where the sample was collected. That the statement does not make this explicit is a separate matter. What next? China's label-race circuit, where large appearance fees and deep East African elite fields meet, has become the AIU's highest-yield testing ground. Aga's case is not isolated — it belongs to a category of road-racing cases where an initial substance violation is compounded by a fabricated explanation. The real question is not when Aga returns; it is whether the system behind her — the one that led her to a fake prescription — will be investigated, and whether any line of that investigation will ever make it into an official record.